{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:49:34Z","timestamp":1792799374681,"version":"4.5.0"},"reference-count":17,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Vasc Endovascular Surg"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Vascular closure devices (VCDs) are essential in modern neuro-interventional procedures, offering advantages over manual compression by accelerating hemostasis, reducing complications, and enabling early ambulation. The Obtura 8F VCD is a novel bioabsorbable closure device designed to enhance safety and procedural efficiency. This study evaluates its efficacy and safety in achieving hemostasis and preventing vascular complications following femoral artery access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This retrospective, single-center study analyzed patients who underwent femoral artery closure with the Obtura 8F VCD. The primary performance endpoint was a successful hemostasis without additional intervention. The primary safety endpoint was the incidence of vascular complications within 30 days and 3 months. Secondary outcomes included time to ambulation and length of hospital stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 100 patients (mean age: 59.48 \u00b1 13.03 years, 64% male) were included. Hemostasis was successfully achieved in 96% of cases, and all patients were able to move the limb within 8 hours post-procedure. During hospitalization, hematoma\/pseudoaneurysm occurred in 6% of patients, with age \u226565 years, hypertension, and diabetes identified as significant risk factors. No evidence of infection was reported at either 30 days or 3 months. The majority of patients (80%) were discharged within 4-7 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Obtura 8F VCD demonstrated high efficacy in achieving hemostasis with a strong safety profile with no major vascular complications. These findings support its use as a reliable alternative to manual compression, facilitating faster patient recovery and potentially reducing hospital resource utilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15385744251375265","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T14:41:58Z","timestamp":1756651318000},"page":"19-27","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety &amp; Effectiveness of the Obtura 8F Vascular Closure Device in Neuro-Interventional Practice: A Retrospective Analysis"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7419-6112","authenticated-orcid":false,"given":"Rasmiranjan","family":"Padhi","sequence":"first","affiliation":[{"name":"GKNM Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virag","family":"Sanjay Shethna","sequence":"additional","affiliation":[{"name":"GKNM Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadeesan","family":"Dhanasekaran","sequence":"additional","affiliation":[{"name":"GKNM Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2085-4428","authenticated-orcid":false,"given":"Kiran","family":"Kumar Shetty","sequence":"additional","affiliation":[{"name":"Meril Life Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016925309136722"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.113.000836"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv375"},{"issue":"4","key":"e_1_3_4_5_2","first-page":"369","article-title":"Update on endovascular treatment of peripheral vascular disease: new Tools, techniques, and indications","volume":"27","author":"Krajcer Z","year":"2000","unstructured":"Krajcer Z, Howell MH. Update on endovascular treatment of peripheral vascular disease: new Tools, techniques, and indications. Tex Heart Inst J. 2000;27(4):369-385.","journal-title":"Tex Heart Inst J"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.001306"},{"issue":"12","key":"e_1_3_4_7_2","first-page":"599","article-title":"Review of vascular closure devices","volume":"22","author":"Schwartz BG","year":"2010","unstructured":"Schwartz BG, Burstein S, Economides C, Kloner RA, Shavelle DM, Mayeda GS. Review of vascular closure devices. J Invasive Cardiol. 2010;22(12):599-607.","journal-title":"J Invasive Cardiol"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.25270\/jic\/21.00081"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.tvir.2015.04.008"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2018.05.019"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.350"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.12.027"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15305"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.06.048"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2010.04.015"},{"issue":"9","key":"e_1_3_4_16_2","first-page":"459","article-title":"Risk of local adverse events following cardiac catheterization by hemostasis device use and gender","volume":"16","author":"Tavris DR","year":"2004","unstructured":"Tavris DR, Gallauresi BA, Lin B, et al. Risk of local adverse events following cardiac catheterization by hemostasis device use and gender. J Invasive Cardiol. 2004;16(9):459-464.","journal-title":"J Invasive Cardiol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000536"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.017"}],"container-title":["Vascular and Endovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15385744251375265","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15385744251375265","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15385744251375265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:36:16Z","timestamp":1777703776000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15385744251375265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/15385744251375265"],"URL":"https:\/\/doi.org\/10.1177\/15385744251375265","relation":{},"ISSN":["1538-5744","1938-9116"],"issn-type":[{"value":"1538-5744","type":"print"},{"value":"1938-9116","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]}}}